XML 46 R39.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Commitments and Contingencies (Tables)
6 Months Ended
Jun. 30, 2024
Commitments And Contingencies [Line Items]  
Schedule Of Royalty Liability Account Roll Forward

The following table shows the activity within the Royalty Liability account during the six months ended June 30, 2024 as well as the effective interest rate (dollars in thousands):

Balance, January 1, 2024

$

145,810

 

Amortization of deferred transaction costs

 

114

 

Non-cash interest expense on liability for sale of future royalties

 

8,517

 

Royalty revenue earned by or payable to Sagard

 

(6,927

)

Balance, June 30, 2024

$

147,514

 

 

 

 

Effective interest rate

11.1% — 11.5%

 

Schedule of Lease Term and Discount Rate

Financing liability information was as follows (dollars in thousands):

 

 

June 30, 2024

 

 

December 31, 2023

 

Weighted average remaining lease term (in years)

 

 

17.3

 

 

 

17.8

 

Weighted average discount rate

 

 

9.0

%

 

 

9.0

%

Lease information was as follows (dollars in thousands):

 

 

June 30, 2024

 

 

December 31, 2023

 

Operating lease right-of-use assets(1)

 

$

4,073

 

 

$

4,685

 

 

 

 

 

 

 

 

Operating lease liability-current(2)

 

$

1,773

 

 

$

1,423

 

Operating lease liability-long-term

 

 

3,272

 

 

 

3,925

 

Total

 

$

5,045

 

 

$

5,348

 

 

 

 

 

 

 

 

Weighted average remaining lease term (in years)

 

 

3.4

 

 

 

3.7

 

Weighted average discount rate

 

 

7.3

%

 

 

7.3

%

_________________________

(1)
Operating right-of-use assets related to vehicles, offices and the manufacturing facility for V-Go are included in other assets in the condensed consolidated balance sheets.
(2)
Operating lease liability – current is included in accrued expenses and other current liabilities in the condensed consolidated balance sheets.
Summary of Lease Information

 

 

Three Months
Ended June 30,

 

 

Six Months
Ended June 30,

 

 

 

2024

 

 

2023

 

 

2024

 

 

2023

 

Interest expense on financing liability

 

$

2,444

 

 

$

2,449

 

 

$

4,891

 

 

$

4,873

 

 

 

Three Months
Ended June 30,

 

 

Six Months
Ended June 30,

 

 

 

2024

 

 

2023

 

 

2024

 

 

2023

 

Operating lease costs

 

$

350

 

 

$

410

 

 

$

698

 

 

$

831

 

Variable lease costs

 

 

9

 

 

 

13

 

 

 

19

 

 

 

49

 

Cash paid

 

 

314

 

 

 

234

 

 

 

546

 

 

 

557

 

Summary of Remaining Financing Liability Payments

The Company's remaining financing liability payments were as follows (in thousands):

 

 

June 30, 2024

 

Remainder of 2024

 

$

5,027

 

2025

 

 

10,269

 

2026

 

 

10,533

 

2027

 

 

10,849

 

2028

 

 

11,174

 

Thereafter

 

 

177,278

 

Total

 

 

225,130

 

Interest payments

 

 

(118,530

)

Debt issuance costs

 

 

(2,571

)

Total financing liability

 

$

104,029

 

Summary of Financing Lease Information

Financing lease information was as follows (dollars in thousands):

 

 

June 30, 2024

 

Financing lease right-of-use asset(1)

 

$

222

 

 

 

 

 

Financing lease liability-current(2)

 

$

39

 

Financing lease liability-long-term

 

 

184

 

Total

 

$

223

 

 

 

 

 

Weighted average remaining lease term (in years)

 

 

4.9

 

Weighted average discount rate

 

 

7.3

%

_________________________

(1)
Financing right-of-use asset is included in other assets in the condensed consolidated balance sheets.
(2)
Financing lease liability – current is included in accrued expenses and other current liabilities in the condensed consolidated balance sheets.
Remaining Purchase Commitments and Estimated Capacity Fee Liability Requirements The Company's remaining purchase commitments and estimated capacity fee liability as of June 30, 2024 were as follows (€ in millions):

 

June 30, 2024

 

 

Remaining Purchase Commitments

 

 

Estimated Capacity Fees

 

2025

 

 

 

 

1.5

 

2026(1)

 

4.2

 

 

 

2.0

 

2027

 

6.0

 

 

 

1.0

 

2028

 

6.0

 

 

 

1.0

 

2029

 

6.0

 

 

 

1.0

 

2030

 

6.0

 

 

 

1.0

 

2031

 

8.0

 

 

 

0.5

 

2032

 

8.0

 

 

 

0.5

 

2033

 

8.0

 

 

 

0.5

 

2034

 

4.4

 

 

 

0.5

 

Total

 

56.6

 

 

 

9.5

 

_________________________

If there is a delay in the availability of insulin with FDA approved inclusion bodies and supply does not begin in 2026 as currently expected, the Company will incur a capacity fee of €750,000 per quarter that the product is not available for purchase.
Schedule of Future Minimum Office And Vehicle Lease Payments

The Company's future minimum office and vehicle lease payments were as follows (in thousands):

 

 

June 30, 2024

 

Remainder of 2024

 

$

918

 

2025

 

 

1,829

 

2026

 

 

1,213

 

2027

 

 

1,135

 

2028

 

 

643

 

Total

 

 

5,738

 

Interest expense

 

 

(693

)

Total operating lease liability

 

$

5,045

 

Audio Visual Equipment  
Commitments And Contingencies [Line Items]  
Summary of Remaining Financing Liability Payments

The Company's remaining financing lease payments were as follows (in thousands):

 

 

June 30, 2024

 

Remainder of 2024

 

$

27

 

2025

 

 

54

 

2026

 

 

54

 

2027

 

 

54

 

2028

 

 

54

 

Thereafter

 

 

23

 

Total

 

 

266

 

Interest payments

 

 

(43

)

Total financing liability

 

$

223